is oral semaglutide safe ADA 2025: Demonstrates Cardiovascular Benefits in SOUL Trial A Retrospective Study Evaluating the

Track your body composition over time, not just your scale weight

Several practical strategies may help reduce the impact of bowel-related side effects whilst continuing retatrutide treatment

NHS England rolled out tirzepatide for weight management in cohorts after NICE TA1026 in December 2024: 3 Cohort 1 (from June 2025): adults with a body mass index (BMI) of 40 or higher and at least four of five weight-related conditions (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)

Getting off GLP-1 medications often leads to significant weight rebound, and researchers want to know if a lower maintenance dose of retatrutide can prevent this

2024 and that analysis was done before the recent CVS Caremark decision to drop coverage for the drug starting in July